What is the role of genomic assays in prostate cancer diagnosis and screening?

Updated: Jan 14, 2019
  • Author: Lanna Cheuck, DO; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print


In a review highlighting advantages and limitations of genomic testing, Falzarano et al note the vast variety of new testing available for aiding in diagnosis and risk stratification for prostate cancer. [38] In addition to the Prolaris/CCP score and Decipher, other genomic assays mentioned in the review include the following:

  • Confirm MDx
  • PCMT
  • Oncotype DX
  • Promark

Advantages of Confirm MDx and PCMT include a high negative predictive value (NPV), which reduces the need for repeat biopsies. [38] Limitations of Confirm MDx and PCMT are their inability to distinguish aggressive from indolent disease, which is a strength of the CCP score and Oncotype DX. [38] As described above, Decipher is unique in that it is a predictor of metastatic disease after RP. [38]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!